Prognostic value of ALBI score in lung cancer patients with liver  metastases and hepatic failure: a single-center experience

Serkan Yaşar; Mustafa Büyükkör; Fatih Tay; Bediz Kurt İnci; Berkan Karabuga; Necla Demir; Ayşe Ocak Duran

Makale detayları

Prognostic value of ALBI score in lung cancer patients with liver metastases and hepatic failure: a single-center experience

Yazarlar:

Serkan Yaşar | Mustafa Büyükkör | Fatih Tay | Bediz Kurt İnci | Berkan Karabuga | Necla Demir | Ayşe Ocak Duran

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.501-505

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355611

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: Lung cancer remains the leading cause of cancer-related mortality worldwide, with especially poor outcomes in the metastatic stage. Liver metastases and subsequent liver failure significantly worsen prognosis. Accurate risk stratification is therefore essential in this setting. The albumin-bilirubin ALBI score, a simple and objective indicator of liver function, may aid in prognostic evaluation. Unlike previous studies, this study specifically focuses on lung cancer patients with liver failure, a clinically distinct and high-risk subgroup. Methods: Clinicopathological data and laboratory parameters were retrospectively retrieved from the hospital information system for patients with histologically confirmed lung cancer and concurrent liver metastases complicated by liver failure. ALBI score was calculated based on peripheral blood test results using the formula: 0.66log10bilirubin, μmolL0.085albumin, gL. Results: The median overall survival mOS was 0.19 months in ALBI grade 3 95 CI: 0.100.28 and 1.54 months in ALBI grade 2 95 CI: 0.192.89, with a statistically significant difference p0.01. Univariate analysis identified NSCLC histology, ALBI grade 3, and chemotherapy during hepatic failure as significant predictors of overall survival. In multivariate analysis, chemotherapy HR: 0.11, p0.001 and ALBI grade 3 HR: 2.31, p0.008 remained independent prognostic factors. Conclusion: ALBI score is a useful prognostic marker for survival after liver failure, with ALBI grade 3 indicating worse outcomes. It may aid in risk stratification and clinical decision-making in this high-risk group.

 Aims: Lung cancer remains the leading cause of cancer-related mortality worldwide, with especially poor outcomes in the metastatic stage. Liver metastases and subsequent liver failure significantly worsen prognosis. Accurate risk stratification is therefore essential in this setting. The albumin-bilirubin ALBI score, a simple and objective indicator of liver function, may aid in prognostic evaluation. Unlike previous studies, this study specifically focuses on lung cancer patients with liver failure, a clinically distinct and high-risk subgroup. Methods: Clinicopathological data and laboratory parameters were retrospectively retrieved from the hospital information system for patients with histologically confirmed lung cancer and concurrent liver metastases complicated by liver failure. ALBI score was calculated based on peripheral blood test results using the formula: 0.66log10bilirubin, μmolL0.085albumin, gL. Results: The median overall survival mOS was 0.19 months in ALBI grade 3 95 CI: 0.100.28 and 1.54 months in ALBI grade 2 95 CI: 0.192.89, with a statistically significant difference p0.01. Univariate analysis identified NSCLC histology, ALBI grade 3, and chemotherapy during hepatic failure as significant predictors of overall survival. In multivariate analysis, chemotherapy HR: 0.11, p0.001 and ALBI grade 3 HR: 2.31, p0.008 remained independent prognostic factors. Conclusion: ALBI score is a useful prognostic marker for survival after liver failure, with ALBI grade 3 indicating worse outcomes. It may aid in risk stratification and clinical decision-making in this high-risk group.

 Aims: Lung cancer remains the leading cause of cancer-related mortality worldwide, with especially poor outcomes in the metastatic stage. Liver metastases and subsequent liver failure significantly worsen prognosis. Accurate risk stratification is therefore essential in this setting. The albumin-bilirubin ALBI score, a simple and objective indicator of liver function, may aid in prognostic evaluation. Unlike previous studies, this study specifically focuses on lung cancer patients with liver failure, a clinically distinct and high-risk subgroup. Methods: Clinicopathological data and laboratory parameters were retrospectively retrieved from the hospital information system for patients with histologically confirmed lung cancer and concurrent liver metastases complicated by liver failure. ALBI score was calculated based on peripheral blood test results using the formula: 0.66log10bilirubin, μmolL0.085albumin, gL. Results: The median overall survival mOS was 0.19 months in ALBI grade 3 95 CI: 0.100.28 and 1.54 months in ALBI grade 2 95 CI: 0.192.89, with a statistically significant difference p0.01. Univariate analysis identified NSCLC histology, ALBI grade 3, and chemotherapy during hepatic failure as significant predictors of overall survival. In multivariate analysis, chemotherapy HR: 0.11, p0.001 and ALBI grade 3 HR: 2.31, p0.008 remained independent prognostic factors. Conclusion: ALBI score is a useful prognostic marker for survival after liver failure, with ALBI grade 3 indicating worse outcomes. It may aid in risk stratification and clinical decision-making in this high-risk group.

 Aims: Lung cancer remains the leading cause of cancer-related mortality worldwide, with especially poor outcomes in the metastatic stage. Liver metastases and subsequent liver failure significantly worsen prognosis. Accurate risk stratification is therefore essential in this setting. The albumin-bilirubin ALBI score, a simple and objective indicator of liver function, may aid in prognostic evaluation. Unlike previous studies, this study specifically focuses on lung cancer patients with liver failure, a clinically distinct and high-risk subgroup. Methods: Clinicopathological data and laboratory parameters were retrospectively retrieved from the hospital information system for patients with histologically confirmed lung cancer and concurrent liver metastases complicated by liver failure. ALBI score was calculated based on peripheral blood test results using the formula: 0.66log10bilirubin, μmolL0.085albumin, gL. Results: The median overall survival mOS was 0.19 months in ALBI grade 3 95 CI: 0.100.28 and 1.54 months in ALBI grade 2 95 CI: 0.192.89, with a statistically significant difference p0.01. Univariate analysis identified NSCLC histology, ALBI grade 3, and chemotherapy during hepatic failure as significant predictors of overall survival. In multivariate analysis, chemotherapy HR: 0.11, p0.001 and ALBI grade 3 HR: 2.31, p0.008 remained independent prognostic factors. Conclusion: ALBI score is a useful prognostic marker for survival after liver failure, with ALBI grade 3 indicating worse outcomes. It may aid in risk stratification and clinical decision-making in this high-risk group.

Makale detayları

Prognostic value of ALBI score in lung cancer patients with liver metastases and hepatic failure: a single-center experience

Yazarlar:

Serkan Yaşar | Mustafa Büyükkör | Fatih Tay | Bediz Kurt İnci | Berkan Karabuga | Necla Demir | Ayşe Ocak Duran

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.501-505

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355611

pISSN:

2718-0115

ALBI

albumin

bilirubin

lung cancerALBI

albumin

bilirubin

lung cancer

Sayı

Makale detayları

Yazarlar: Serkan Yaşar | Mustafa Büyükkör | Fatih Tay | Bediz Kurt İnci | Berkan Karabuga | Necla Demir | Ayşe Ocak Duran

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Klinik Onkoloji

Dergi: Anatolian Current Medical Journal Vol.7 Issue 4, pp.501-505

Belge Tipi: Makale

Yayın Tarihi: 7/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001355611

pISSN: 2718-0115

Sayı

Yazarlar:

Serkan Yaşar | Mustafa Büyükkör | Fatih Tay | Bediz Kurt İnci | Berkan Karabuga | Necla Demir | Ayşe Ocak Duran

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji

Dergi:

Anatolian Current Medical Journal Vol.7 Issue 4, pp.501-505

Belge Tipi:

Makale

Yayın Tarihi:

7/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001355611

pISSN:

2718-0115